Please do not leave this page until complete. This can take a few moments.
New Haven’s Trevi Therapeutics Inc. said it has raised a Series B financing of $25 million to initiate trials for its anti-itching drug Nalbuphine ER.
The round was led by TPG Biotech, which previously invested $12.8 million in Trevi. Angel investors also participated.
Nalbuphine ER is an oral extended release formulation of nalbuphine hydrochloride, a semi-synthetic opioid which Trevi said has only previously been approved as an injectable treatment.
Trevi, which was founded in 2011 and recently completed a Phase 1 trial on patients on hemodialysis, is planning trials to test its formulation on two severe itch conditions known as uremic pruritis and prurigo nodularis. It expects to commence trials in the third quarter.
The Hartford Business Journal 2025 Charity Event Guide is the annual resource publication highlighting the top charity events in 2025.
Learn moreHartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
SubscribeDelivering vital marketplace content and context to senior decision-makers throughout Connecticut ...
All Year Long!
The Hartford Business Journal 2025 Charity Event Guide is the annual resource publication highlighting the top charity events in 2025.
Hartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
Delivering vital marketplace content and context to senior decision-makers throughout Connecticut ...
All Year Long!
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments